Debrisoquin (hydroiodide)

Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624) . Debrisoquin is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for antiviral research[1].

Product Specifications

CAS Number

[1052540-65-4]

Product Name Alternative

Debrisoquine (hydroiodide) ; Isocaramidine (hydroiodide) ; Ro 5-3307/1 (hydroiodide)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

SARS-CoV; Ser/Thr Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/debrisoquin-hydroiodide.html

Concentration

10mM

Purity

99.84

Solubility

DMSO : 175 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N=C(N1CC2=C(CC1)C=CC=C2)N.I

Molecular Formula

C10H14IN3

Molecular Weight

303.15

Precautions

H302, H315, H319, H335

References & Citations

[1]Amanda L. Peiffer, et.al.TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform.ACS Medicinal Chemistry Letters 2023 14 (6), 860-866.